Merck pulls Recombivax lot on cracked-vial risk; India's Elder Pharma to buy OTC drugmaker;

 @FiercePharma: Chile's CFR Pharma offers $1.3B for leading South African drug maker Adcock Ingram. Will Bidvest come back? Article | Follow @FiercePharma

 @CarlyHFierce: ICYMI: King Pharmaceuticals settles for $2.2M after violating pharma emissions standards. More | Follow @CarlyHFierce

> Merck ($MRK) pulled one lot of its Recombivax hepatitis B vaccine because of the potential for cracked vials, which could undermine sterility. Report

> Elder Pharma's U.K. subsidiary snapped up Max Healthcare to re-enter the over-the-counter pharmaceuticals market. Report

> GlaxoSmithKline ($GSK) is rolling out new versions of its Eno brand antacid in India. Report

> The FDA warned that Daiichi Sankyo's blood pressure drugs Benicar, Benicar HCT, Azor and Tribenzor can cause severe chronic diarrhea and weight loss in some patients. Report

> Merz won FDA approval for a stronger formulation of Naftin, an antifungal gel. Report

> The FDA's advertising watchdogs took Johnson & Johnson ($JNJ) to task for a Xarelto ad that they said was designed to minimize risk disclosures. Report

> GlaxoSmithKline lost its most recent appeal on behalf of its wind-turbine project in Scotland. Report

Medical Device News

 @FierceMedDev: Device tax opponents may have gained their opening. Item | Follow @FierceMedDev

 @MarkHFierce: Give us your FMD Fierce 15 nominations today. And spread the word.... More | Follow @MarkHFierce

 @DamianFierce: GI Dynamics has raised $52.2M to get its anti-obesity device through the FDA process. Story | Follow @DamianFierce

> Philips brings updated interventional X-ray system to U.S. market. News

> Clock ticking on vaginal mesh lawsuits against J&J, others. Story

> Study links sales reps at hospitals to higher healthcare costs. More 

Biotech News

 @FierceBiotech: Researchers spotlight two cases of eradicated HIV infection. Story | Follow @FierceBiotech

 @JohnCFierce: FDA cuts the regulatory fuse on Roche's heir to Rituxan. More | Follow @JohnCFierce

 @RyanMFierce: GlaxoSmithKline, J&J make early progress with monthly HIV combo. News | Follow @RyanMFierce

 @EmilyMFierce: Texas A&M launches multimillion-dollar genomics research project. Item | Follow @EmilyMFierce

> Report: Sanofi trims R&D jobs in France in scaled-down reorganization. News

> Biogen R&D exec Gilman hits the exit door. Item

Drug Delivery News

 @MichaelGFierce:  Mass-produced nanoparticles for drug delivery show market potential. More | Follow @MichaelGFierce

> Avanir drops $110M on novel inhaled-delivery migraine device. News

> UVA researchers find enzyme target for glioblastoma, cancer treatment. Story

> High-dose schizophrenia treatment crosses blood-brain barrier. Read

> Alnylam reports two more positive trials in RNAi arena. More 

And Finally... The number of overdose deaths from opioid abuse grew faster among women than men over the past decade, a new study found. Report

Suggested Articles

The CD19 antibody, used in tandem with Celgene's Revlimid, represents the first FDA approval in second-line diffuse large B-cell lymphoma.

Sanofi has faced a probe into birth defects tied to seizure med Depakine for years. Now, the investigation is moving forward on manslaughter charges.

Pfizer launched a multichannel awareness campaign centered on a first-ever radio station dedicated solely to metastatic breast cancer.